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1. Introduction
   Enterobacteriaceae are a family of Gram-negative 
bacilli that includes Escherichia coli (E. coli), Klebsiella 
pneumoniae (K. pneumoniae) and other clinically important 
species of the pathogenic bacteria. These organisms cause 
serious infections such as bacteraemia, pneumonia, urinary 
tract and wound infections[1]. According to the World 
Health Organization (WHO), every year approximately 4.5 
billion cases of infections by these organisms have been 
reported of which 1.9 million end in death[2]. In addition to 
Enterobacteriaceae, Pseudomonas species, Acinetobacter 
species and Staphylococcus species also cause various types 
of infections in human[3-9]. It is increasingly being reported 
that β-lactam antimicrobial agents are widely used to 
treat the infections caused by these organisms accounting 
for over 50% of all antibiotics use[10]. However, in recent 
years, treatment of Enterobacteriaceae, Pseudomonas spp. 
Staphylococcus spp. and Acinetobacter spp. is becoming 
tough because of increasing antibiotic resistance[11,12]. 
There are many factors involved in the development of 
antibiotic resistance including over expression of efflux 
pump[13], acquisition of extended-spectrum β-lactamases 
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Conclusions: Results of the present study indicated that majority of the isolates was susceptible 
to CSE1034 and it could be a potent antibacterial agent for the treatment of severe bacterial 
infections caused by such organisms.
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(ESBLs) and metallo-β-lactamases[14,15], target site or outer 
membrane modification[16].
   Among these factors,  prevalence of antibiotic 
resistance to beta-lactam antibiotics among members of 
Enterobacteriaceae, Pseudomonas spp. and Acinetobacter 
spp. because of ESBL has been steadily increasing across 
the world over the past few years, resulting in the limitation 
of therapeutic options[11,12,14,15,17]. The overall prevalence 
of ESBL producers is found to vary greatly in different 
geographical areas such as from 66.7% to 73.5% in India[9,18], 
54.7% to 59.2% in Iran, 41% in United Arab Emirates[19,20]. 
   The ESBL enzyme has resistance not only to broad-
spectrum cephalosporins, including oxymino-β-lactam 
antibiotics but also to other commonly used antibiotics 
including aminoglycosides and quinolones[21,22]. A number 
of studies have demonstrated the decreased susceptibility of 
Enterobacteriaceae to cephalosporins and other drugs[23-27]. 
Similarly, the decreased susceptibility rates of Pseudomonas 
aeruginosa (P. aeruginosa) and Acinetobacter baumannii 
(A. baumannii) to β-lactams, carbapenems, quinolones 
and aminoglycosides have been reported in various 
countries[11,28-30].
   The increasing rate of the antibiotic resistance and its 
impact on treatment failure encouraged us to study newly 
reported concept of antibiotic adjuvant entity by which 
the increasing failure rate of antibiotics in treatment can 
be controlled. Information regarding the prevalence of 
antimicrobial resistance in pathogens can be used for 
selecting an alternative option.
   Data on the prevalence of TEM, SHV, Amp-C, KPC and 
CTX-M variants in Enterobacteriaceae (E. coli and K. 
pneumoniae) and non-fermenting Gram-negative bacilli 
(A. baumannii and P. aeruginosa) from Indian hospitals 
are needed. Therefore, the current study was undertaken 
to study the molecular characterisation of the selected 
ESBL producing isolates. The study also analysed the 
susceptibility behaviour of these isolates to different 
antibiotics including CSE1034, a new antibiotic adjuvant 
entity which is a combination of β-lactam, β-lactamase 
inhibitor and nonantibiotic adjuvant altogether termed as 
CSE1034 with other antibiotics against these isolates. 
2. Materials and methods
2.1. Clinical specimen collection and their identification
   All the specimens were collected from different hospitals 
of India. The name of hospitals can not be disclosed due 
to confidential agreement. This study was conducted from 
January 2013 to March 2014. All the specimens including 
blood, urine, sputum and pus were isolated and identified 
isolates according to the standard microbiological 
techniques and VITEK-2 (BioMérieux, Marcy l’Etoile, 
France)[31]. Before use, all the specimens were inoculated in 
Soyabean-Casein Digest Agar (Hi-Media, Mumbai, India), 
and incubated at 37 °C for overnight. At least three to five 
colonies of each specimen were selected from the Soyabean-
Casein Digest Agar plate and were transferred into a tube 
containing 10 mL of sterile Mueller-Hinton broth (Hi-Media, 
Mumbai, India) to produce a suspension which matched the 
turbidity standard of 0.5 McFarland standard. 
2.2. Collection procedure of clinical isolates and quality 
control points
   The clinical isolates were collected using the procedures 
mentioned in the manual for the laboratory identification and 
antimicrobial susceptibility testing of bacterial pathogens of 
public health importance in the developing world. Quality 
control points were also followed while collecting the strains 
as mentioned in the above guidelines.
2.3. Antimicrobial agents
   CSE1034 containing ceftriaxone sodium 1 g plus sulbactam 
sodium 0.5 g along with 37 mg adjuvant disodium edetate 
(CSE1034 of Venus Remedies Limited, India), amoxicillin plus 
potassium clavulanate 1.2 g (Augmentin, GlaxoSmithKline, 
Pharmaceuticals Limited, Mumbai, India), piperacillin plus 
tazobactam 4.5 g (Zosyn, Wyeth Pharmaceuticals, Mumbai, 
India), meropenem 1 g (Meronem, AstraZeneca Pharma India 
Limited, Banglore, India), imipenem plus cilastatin 500 mg 
(Imecila, Nicholas Piramal, Limited, India) cefoperazone plus 
sulbactam 1 g (Magnex, Pfizer Limited, Mumbai, India) were 
used in the study. All the drugs were reconstituted in sterile 
water for injection.
2.4. Phenotypic screening of isolates for ESBL
   Screening of clinical isolates for ESBL production was 
performed according to the procedures as recommended 
by the Clinical and Laboratory Standards Institute (CLSI)
[32], using indicator cephalosporins, ceftriaxone (30 µg), 
ceftazidime (30 µg) and cefotaxime (30 µg). The respective 
zone size was interpreted according to the recommendations 
of CLSI. Isolates exhibiting zone size ≤22 for ceftazidime 
and ≤27 with cefotaxime were considered as possible ESBL 
producers. Further, testing was done using ceftazidime-
clavulanic acid (30/10 µg) and cefotaxime-clavulanic acid 
(30/10 µg) to confirm the ESBL production according to the 
CLSI[32].  
2.5. Detection of varinats of ESBL genes
2.5.1. DNA isolation
   DNA isolation from all the clinical isolates phenotypically 
confirmed to be ESBL positive and was carried out according 
to the method of alkaline lysis[33]. Five millilitre of overnight 
grown culture was used for the DNA isolation. 
2.5.2. PCR 
   The detection of variants of ESBL genes, such as TEM-1, 
TEM-3, TEM-50, SHV-1, SHV-4, SHV-10, SHV-28, Amp-C, 
OXA-2, OXA-10, OXA-23, OXA-48, KPC-1, KPC-2, CTX-
M-1, CTX-M-9 and Bla-Z was carried out as described 
previously[34-46]. The primers used in the study are shown 
in Table 1. All of the respective primers were obtained from 
Sigma Aldrich Chemicals Pvt. Ltd., Banglore, India. For 
PCR amplifications, about 200 pg of DNA was added to 20 µL 
mixture containing 0.5 mmol/L of dNTPs, 1.25 µmol/L of each 
primer and 3.0 µL/IU of Taq polymerase (Banglore Genei) in 
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1伊 PCR buffer. Amplification was performed in a Eppendorf 
thermal cycler (Germany). 
Table 1 
Oligonucleotides used in the study for each tested genes.
Primer Primer sequences (5'-3') Amplicon (base 
pair)
References
TEM-1 F-5' ATG AGT ATT CAA CAT TTC CG-3' 858 [41]
R-5' CCA ATG CTT ATT CAG TGA GG-3'
TEM-3 F-ATA AAA TTC TTG AAG AC-3' 652 [41]
R-TTA CCA ATG CTT AAT CA-3'
TEM-50 F-AAG ACG AAA GGG CCT CGT G 1074 [38]
R-GGT CTG ACA GTT ACC AAT GC
SHV-1 F-5' CTG GGA AAC GGA ACT GAA TG-3' 308 [41]
R-5' GGG GTA TCC CGC AGA TAA AT-3'
SHV-4 F-5' TCA GCG AAA AAC ACC TTG C-3' 322 [34]
R-5' CGA TCG TCC ACC ATC CAG TG-3'
SHV-10 F-5' CCG ATA AGA CCG GAG TTC GC-3' 248 [34]
F-5' AGT CAT ATC GCC CGG CAC-3'
SHV-28 F-5' ATT TGT CGC TTC TTT ACT CGC-3' 1052 [40]
R-5' GGT CAA AGG TAA CGC CAT AAA-3'
AmpC F-5 CCC CGC TTA TAG AGC AAC AA-3 634 [35]
R-5 TCA ATG GTC GAC TTC ACA CC-3
OXA-2 5’-GCC AAA GGC ACG ATA GTT GT-3’ 701 [38]
5’-GCG TCC GAG TTG ACT GCC GG-3’
OXA-10 5’-TCT TTC GAG TAC GGC ATT AGC-3’ 759 [38]
5’-CCA ATG ATG CCC TCA CTT TCC-3’
OXA-23 5’-GAT CGG ATT GGA GAA CCA GA-3’ 501 [46]
5’-ATT TCT GAC CGC ATT TCC AT-3’
OXA-48 5’-GCG TGG TTA AGG ATG AAC AC-3’ 438 [42]
5’-CAT CAA GTT CAA CCC AAC CG-3’
KPC-1 F: 5'-CTT GCT GCC GCT GTG CTG-3' 489 [45]
R: 5’-GCA GGT TCC GGT TTT GTC TC-3'
KPC-2 F: 5'-GCT ACA CCT AGC TCC ACC TTC-3' 989 [43]
R: 5'-GCA TGG ATT ACC AAC CAC TGT-3'
CTX-M-1 F: 5' GAC GAT GTC ACT GGC TGA GC 3' 499 [41]
R: 5’ AGC CGC CGA CGC TAA TAC A 3’
CTX-M-9 F: 5' TAT TGG GAG TTT GAG ATG GT 3' 932 [38]
R: 5’ TCC TTC AAC TCA GCA AAA GT 3
Bla-Z F: 5' AAG AGA TTT GCC TAT GCT TC 3' 517 [36]
R: 5’ GCT TGA CCA CTT TTA TCA GC3
F: Sense primer; R: Antisense primer. 
2.5.3. Gel electrophoresis
   The amplified products were separated in 1.5% agarose 
gel containing 2.5 µL of 10 mg/mL ethidium bromide. The 
gel was run at 70 v for 1 h. The gel images were taken under 
ultraviolet light using gel documentation system (Bio-Rad, 
USA). A 100 bp ladder (Banglore Genie) was used to measure 
the molecular weights of amplified products. The images of 
ethidium bromide stained DNA bands were visualized using 
a gel documentation system (Bio-Rad, USA).
2.6. Antibiotic susceptibility testing
   Susceptibility to various classes of antibiotics were done 
by two methods: minimum inhibitory concentration (MIC) and 
antibiotic susceptibility (AST).
2.7. MIC 
   MIC was determined according to the guidelines of CLSI[32]. 
E. coli ATCC 35218 (TEM), K. pneumoniae ATCC 700603 (SHV), 
Enterobacter cloacae ATCC BAA-1143 (AmpC) (E. cloacae), K. 
pneumoniae ATCC BAA-1705 (KPC), E. coli NCTC 13302 (OXA) 
and E. coli NCTC 13353 (CTX-M-15), were procured from 
LGC, Promochem, Bangalore, India, which were used as 
positive controls. MIC value represents the lowest dilution at 
which bacteria fail to grow. Serial two fold dilutions of the 
drugs from 0.031 25 to 1 024 µg/mL were made using Cation-
Adjusted Mueller-Hinton (Hi Media, Mumbai, India) broth in 
wells of 96-well plate. 
2.8. AST 
   AST testing of the drugs were determined by disc diffusion 
method according to the CLSI. Positive controls were the 
same which were used in MIC study. Inoculum containing 
10
6 CFU/mL of test strain was spread with a sterile swab on 
a Petri dish containing Mueller-Hinton agar and the plates 
were dried. Then, disc of the respective antibiotic was placed 
in the plate and allowed to diffuse at room temperature. The 
plates were incubated in the upright position at 37 °C for 18 
h. After incubation the zone of inhibition around the disc 
was measured in millimeter, and then was averaged and the 
mean values were recorded. The discs of CSE1034 (30:15 µg), 
piperacillin plus tazobactam (100:10 µg), amoxicillin plus 
clavulanic acid (20:10 µg), cefoperazone plus sulbactam (75:30 
µg), imipenem plus cilastatin (10 µg) and meropenem (10 µg) 
were obtained from HiMedia (Mumbai, India). All the test 
were repeated 3 times and results were expressed as mean依
SD values.
3. Results
3.1. Isolation of clinical isolate from specimens
   Out of 3 816 clinical specimens, 1 365 specimens were 
sterile; 2 451 specimens showed the growth of which 
1 788 isolates were of Mycoplasma, Candida albicans, 
Haemophilus influenzae, Mycobacterium tuberculosis, 
Salmonells typhi, Staphylococcus epidermidis, Sterptococcus 
pyogenes, Nisseria spp., Burkholderia spp. which were not 
part of study. The remaining specimens showed the growth 
of 663 isolates which includes P. aeruginosa (264/663, 39.8%) 
followed by E. coli (218/663, 32.8%), A. baumannii (72/663, 
10.8%), Klebsiella oxytoca (K. oxytoca) (63/663; 9.5%), K. 
pneumoniae (30/663; 4.5%) and Staphylococcus aureus (S. 
aureus) (16/663; 2.4%) (Table 2).
Table 2 
Isolation of target clinical isolates from different clinical specimens.
Name of the 
specimens
Number of 
specimens
A. 
baumannii
E. 
coli
K. 
pneumoniae
K. 
oxytoca
P. 
aeruginosa
S. aureus
Blood 749 16 46 6 13 41 1
Urine 1 088 8 129 4 8 34 4
Sputum 731 35 23 17 33 31 1
Pus 1 248 13 20 3 9 158 10
Total 3 816 72 218 30 63 264 16
3.2. Detection of ESBL
   Among the 663 isolates, phenotypical 87.6% (n=581) isolates 
were found to be ESBL positive by disc diffusion method. 
Further, genotypic characterization of the same isolates 
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with PCR revealed approximately 82.5% (n=547) isolates 
were ESBL positive, and there was 5.1% decrease in the ESBL 
positive isolates when analyzed with genotypic method. PCR 
results indicated that approximately 89.0% of P. aeruginosa 
isolates were positive for ESBL followed by E. coli (85.3%), 
K. pneumoniae (76.6%), K. oxytoca (73.0%), A. baumannii 
(72.2%) and S. aureus (31.2%) (Table 3). For further study only 
genotypically characterized ESBL isolates were used.
Table 3 
Detection of ESBLs among clinical isolates by disc diffusion and PCR 
methods.
Name of species 
(total)
No. of isolates positive for 
ESBL by disc diffusion (%)
No. of isolates positive 
for ESBL by PCR (%)
A. baumannii (72)   54 (75.0)   52 (72.2)
E. coli (218) 196 (89.9) 186 (85.3)
K. pneumoniae (30)   24 (80.0)   23 (76.6)
K. oxytoca (63)   54 (85.7)   46 (73.0)
P. aeruginosa (264) 245 (92.8) 235 (89.0)
S. aureus (16)    8 (50.0)    5 (31.3)
Total (663) 581 (87.6) 547 (82.5)
3.3. Diversity of ESBLs
   PCR analyses using specific primers for class A, C and D 
β-lactamase genes revealed the following frequencies: TEM 
type ESBLs (blaTEM-1, blaTEM-3, blaTEM-50) were the most 
frequently detected, followed by SHV type ESBLs (SHV-1, 
SHV-4, SHV-10, SHV-28), OXA type ESBLs (OXA-2, OXA-10, 
OXA-23, OXA-48) , CTX-M type ESBLs (CTX-M-1, CTX-M-9), 
AmpC , KPC type ESBLs (KPC-1, KPC-2) and blaZ (Table 4).
3.4. MIC
   The MIC values of CSE1034, piperacillin plus tazobactam, 
amoxicillin plus clavulanic acid, cefoperazone plus 
sulbactam, imipenem plus cilastatin and meropenem were 
determined against all of the selected clinical isolates 
and presented in Table 5. MIC values of CSE1034 for 95.7%, 
92.3%, 91.3%, 93.5%, 94.9%, and 93.3% isolates of E. coli, A. 
baumannii, K. pneumoniae, K. oxytoca, P. aeruginosa and 
S. aureus, respectively were between 0.125 and 8.000 µg/mL 
whereas penems (meropenem and imipenem plus cilastatin) 
MIC ranged from 0.125 to 1.000 µg/mL for 83.9% to 93.3% 
isolates for the same isolates. Piperacillin plus tazobactam 
exhibited MIC value of 4.000-16.000 µg/mL for 45.7% isolates 
of E. coli while 38.5%, 34.8%, 41.3%, 38.7% and 36.0% isolates 
of A. baumannii, K. pneumoniae, K. oxytoca, P. aeruginosa 
and S. aureus respectively with MIC values of 8.000 to 16.000 
µg/mL, respectively. Amoxycillin plus clavulanic acid 
exhibited MIC values of 4.000-8.000 µg/mL against 35.5%, 
28.8%, 26.0%, 26.0%, 25.9% and 25.3% isolates of E. coli, A. 
baumannii, K. pneumoniae, K. oxytoca, P. aeruginosa and S. 
aureus, respectively. Cefoperazone plus sulbactam produced 
MIC values 8.000-16.000 µg/mL against 31.2%, 25.0%, 21.7%, 
21.7%, 23.8%, and 22.7% isolates of E. coli, A. baumannii, 
K. pneumoniae, K. oxytoca, P. aeruginosa and S. aureus, 
respectively. The detailed results are shown in the Table 5. 
3.5. AST
   The antibiotic susceptibility profile was determined by 
disc diffusion method and results are presented in Table 
6. Of the drugs included in the study, CSE1034 seems to be 
more efficacious. Approximately, more than 90% isolates 
were susceptible to CSE1034 with AST values between 23 and 
29 mm. Imipenem plus cilastatin was found second most 
active agent with approximately 90% isolates of E. coli, A. 
baumannii, K. pneumoniae, K. oxytoca, P. aeruginosa and S. 
aureus were susceptible with AST values 16-35 mm whereas 
>80% isolates showed susceptibility to meropenem with 16-
29 mm. Piperacillin plus tazobactam was susceptible in 
<45% isolates with AST values 22-35 mm. Amoxycillin plus 
clavulanic acid found to be susceptible to <35% isolates with 
AST values 18-31 mm. Cefoperazone plus sulbactam found 
to be susceptible to <31% with AST values 21-30 mm. The 
detailed results are shown in the Table 6.
4. Discussion
   ESBLs continue to be the leading cause of resistance to 
β-lactam antibiotics among Gram-negative bacteria. There 
has been increased incidence and prevalence of ESBLs 
which show a wide spread in hospital settings worldwide[47]. 
In this study, 663 clinical isolates of Gram-negative and 
Gram-positive isolates were collected from various clinical 
specimens and were subjected to screening for ESBLs. In our 
study, approximately 87.6% of the isolates were observed to 
be ESBL positive by disc diffusion methods. However, when 
the same strains were processed to check the positivity 
of ESBL with PCR as it is considered as gold standard only 
82.5% of isolates were confirmed to be ESBL positive. These 
results suggest that disc diffusion method may have some 
false detection. Previous studies also demonstrated the 
steadily increasing frequency of ESBLs 50% to 85% in A. 
baumannii[48,49], 4% to 78% in Klebsiella species[50-52], 46% 
to 79% in E. coli[53,54], 45% to 53.9% in P. aeruginosa[55,56]. 
Table 4 
Distribution of variants of ESBL enzymes in different bacterial species.
Species (no. of ESBL positive 
isolates by PCR, n=547)
TEM-1 TEM-3 TEM-50 SHV-1 SHV-4 SHV-10 SHV-28 AmpC OXA-2 OXA-10 OXA-23 OXA-48 KPC-1 KPC-2 CTX-M-1 CTX-M-9 Bla-Z
A. baumannii (52) 5 5 6 10 7 - - 3 4 - - 12 - - - - -
E. coli (186) 37 32 - 24 20 10 5 14 - - - 23 - - - 21 -
K. pneumoniae (23) 5 5 - 1 - - - - - - - - 6 6 - - -
K. oxytoca (46) 10 - - 10 - - - - - - - 6 8 8 - 4 -
P. aeruginosa (235) 34 33 14 31 - 20 - 16 5 - - 42 - - 15 25 -
S. aureus (5) - - - - - - - - - - - - - - - - 5
Most of the isolates contain more than one ESBL genes.
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Increased prevalence of ESBL in our community is suggested 
to be due to intense prescription of the third generation 
cephalosporins in hospitals and the dissemination of these 
organisms by inappropriate hygienic measures. The results 
of the antibiotic susceptibility testing performed on the all 
chosen clinical isolates showed that CSE1034 was the most 
active agent and susceptibility rates of it against the studied 
isolates were very close to the penems (meropenem and 
imipenem plus cilastatin). CSE1034 however was observed 
to show an intermediate and resistant trend against higher 
OXA types and a few Amp-C types. Earlier studies also 
supports the higher susceptibilities of CSE1034 against 
these isolates[56,57]. Less susceptibility of piperacillin 
plus tazobactam in Enterobacteriaceae (E. coli and K. 
pneumoniae) and non-Enterobacteriaceae (A. baumannii 
and P. aeruginosa) has been reported in India[58-60], which 
is in line with current findings with susceptibility <50% 
against most pathogens. Several studies have also reported 
meropenem resistance in Enterobacteriaceae and non-
Enterobacteriaceae isolated from India and abroad[59,61].
   In the current study, resistance to meropenem was 
18.7% for P. aerugionsa which are in line with the result 
of an earlier study where resistance to meropenem for P. 
aeruginosa was 20.3%[49]. The resistance to meropenem in 
A. baumannii was 17.3% in our study which was observed 
to be in accordance with a previous report[49]. Furthermore, 
our data shows 17.4% of K. pneumoniae and 9.3% of E. coli 
isolates were resistant to meropenem. The resistance to 
meropenem in these isolates probably results from reduced 
accumulation of drug or over activation of efflux pump[62]. 
A very high susceptibility of CSE1034 against these isolates 
is likely to be associated with synergistic activity of 
components.
   Results of this study demonstrate that the frequency of 
ESBL mediated resistance among the clinical isolates has 
been increasing and the drugs commonly used for the 
treatment of infections appear to be resistant caused by ESBL 
producing organisms. Data obtained from this investigation 
clearly demonstrate the potent in vitro activity of CSE1034 
against ESBL producing organisms. Hence, in the case of 
infection with ESBL producing organisms, CSE1034 can be a 
drug to be chosen for the treatment.
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Table 5 
Comparative MIC values of ESBL producing strains.
Name of micro-organisms
MIC values of drugs (µg/mL)
Total No. of 
strains (547 
clinical 
isolates)
Ceftriaxone plus sulbactam 
(CSE1034)
Piperacillin plus 
tazobactam
Amoxicillin plus 
clavulanic acid
Cefoperazone plus 
sulbactam
Imipenem plus 
cilastatin
Meropenem
S I R S I R S I R S I R S I R S I R
E. coli 186 0.125-8.000 16-32 64-128 4-16 32-64 128-256 4-8 16 32-512 8-16 32 64-512 0.125-1.000 2 4-32 0.50-1.00 2 4-32
A. baumannii 52 0.250-8.000 16-32 64-128 8-16 32-64 128-512 4-8 16 32-512 8-16 32 64-512 0.125-1.000 2 4-16 0.50-1.00 2 4-64
K. pneumoniae 23 0.250-8.000 16-32 64-128 8-16 32-64 128-256 4-8 16 32-512 8-16 32 64-512 0.125-1.000 2 4-16 0.25-1.00 2 4-32
K. oxytocca 46 0.500-8.000 16-32 64-128 8-16 32-64 128-256 4-8 16 32-512 8-16 32 64-512 0.125-1.000 2 4-32 0.50-1.00 2 4-32
P. aeruginosa 235 1.000-8.000 16-32 64-128 8-16 32-64 128-512 4-8 16 32-512 8-16 32 64-512 0.125-1.000 2 4-16 0.5-1.00 2 8-64
S. aureus 5 0.125-8.000 16-32 64-128 8-16 32-64 128-256 4-8 16 32-512 8-16 32 64-512 0.125-1.000 2 4-16 0.25-1.00 2 4-16
E. coli ATCC 35218 (TEM) 1 0.500 4 8 8 0.250 0.25
K. pneumoniae ATCC 700603  (SHV) 1 0.500 4 8 8 0.250 0.25
Enterobacter cloacae ATCC BAA-1143 (AmpC) 1 2.000 8 8 8 0.500 0.25
K. pneumoniae ATCC BAA-1705 (KPC) 1 8.000 16 32 16 1.000 2.00
E. coli NCTC 13302 (OXA) 1 8.000 32 16 32 2.000 2.00
E. coli NCTC 13353 (CTX-M-15) 1 1.000 8 8 8 0.500 0.50
S: Susceptible; I: Intermediate; R: Resistance. E. coli ATCC 25922 was used as a quality control strain.
Table 6  
Comparative antimicrobial susceptibility of ESBL producing strains.
Name of micro-organisms
Total No. 
of strains
Inhibition zone of drugs (mm)
Ceftriaxone plus 
sulbactam (CSE1034)
Piperacillin plus 
tazobactam
Amoxicillin plus 
clavulanic acid
Cefoperazone plus 
sulbactam
Imipenem plus 
cilastatin
Meropenem
S I R S I R S I R S I R S I R S I R
E. coli 186 25-29 20-22 10-19 22-29 18-20 7-17 19-22 15-18 7-14 21-25 16-20 10-15 23-33 20-22 11-19 23-29 20-22 11-19
A. baumannii 52 23-28 14-20 7-13 22-25 18-20 11-17 18-24 15-17 8-14 21-28 18-20 13-17 16-27 14-15 10-13 16-27 14-15 10-13
K. pneumoniae 23 23-29 20-22 8-19 22-28 18-20 9-17 19-24 15-18 11-14 21-29 16-20 10-15 23-29 20-22 15-19 23-29 20-22 13-19
K. oxytocca 46 24-29 20-22 11-19 22-30 18-20 8-17 19-25 15-18 9-14 21-30 16-20 12-15 23-35 20-22 9-19 23-29 20-22 9-19
P. aeruginosa 235 23-29 14-20 10-13 22-35 15-20 11-14 18-27 15-17 11-14 22-29 18-20 13-17 19-33 16-18 10-15 19-24 16-18 7-15
S. aureus 5 23-30 14-20 10-13 22-25 15-20 11-14 21-31 15-20 13-16 21-25 16-20 12-15 19-30 14-15 7-13 19-33 14-15 10-13
E. coli ATCC 35218 (TEM) 1 29 22 21 21 27 26
K. pneumoniae ATCC 700603  (SHV) 1 31 23 22 22 29 29
E. cloacae ATCC BAA-1143 (AmpC) 1 28 15 20 19 30 27
K. pneumoniae ATCC BAA-1705 (KPC) 1 25 23 17 18 25 22
E. coli NCTC 13302 (OXA) 1 26 19 13 17 24 23
E. coli NCTC 13353 (CTX-M-15) 1 27 20 22 21 28 24
S: Susceptible; I: Intermediate; R: Resistance. E. coli ATCC 25922 was used as a quality control strain.
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